Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at the upcoming European Society of Clinical Microbiology and Infectious Diseases (ESCMID)/American Society For Microbiology (ASM) Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance to be held in Lisbon, Portugal, September 4-7, 2018.
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at the upcoming European Society of Clinical Microbiology and Infectious Diseases (ESCMID)/American Society For Microbiology (ASM) Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance to be held in Lisbon, Portugal, September 4-7, 2018.
This conference focuses on the development of new antimicrobial agents for antimicrobial resistance. It is a multidisciplinary meeting that involves basic scientists, clinical academics, regulatory bodies, funding bodies and the pharmaceutical industry. Its scope stretches from chemistry to clinical development, from neonates to adults, from bacteria to fungi – all with a global perspective.
David Huang, MD, Chief Medical Officer of Motif Bio, will give a presentation on iclaprim as part of the State of the Art Lecture: New Antibacterial Agents on September 5th, 10:10 AM CET.
In addition, four posters on iclaprim will be presented at the conference. These will be on display throughout the event, September 4-7.
1. The Safety of Iclaprim among Diabetic Patients for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Pooled REVIVE Studies
Abstract number: 49
Abstract category: Drug Development
2. Surveillance of Iclaprim Activity: In Vitro Susceptibility of Drug-Susceptible and -Resistant Beta-hemolytic Streptococci Collected During 2012-2016 from Skin and Skin Structure Infections
Abstract number: 50
Abstract category: Drug Development
3. Iclaprim Activity Against Clinical Isolates Causing Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Phase 3 REVIVE-1 and REVIVE-2 Studies
Abstract number: 52
Abstract category: Drug Development
4. Surveillance of Iclaprim Activity: In Vitro Susceptibility of Gram-Positive Skin and Skin Structure Pathogens Collected During 2004-2016
Abstract number: 60
Abstract category: Drug Development
The posters will be available in the Development Programs – Publications section of Motif Bio’s website following the live event.
For further information please contact:
| Motif Bio plc | ||
| Graham Lumsden (Chief Executive Officer) |
| |
|
| ||
| Walbrook PR Ltd. (UK FINANCIAL PR & IR) | +44 (0) 20 7933 8780 | |
| Paul McManus/Helen Cresswell/Lianne Cawthorne | ||
|
| ||
| MC Services AG (EUROPEAN IR) | +49 (0)89 210 2280 | |
| Raimund Gabriel | ||
|
| ||
| Solebury Trout (US IR) | + 1 (646) 378-2963 | |
| Meggie Purcell | ||
|
| ||
| Russo Partners (US PR) | +1 (858) 717-2310 or +1 (212) 845 4272 | |
| David Schull | ||
| Travis Kruse, Ph.D. | ||
